Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
21.07
+0.09 (0.43%)
At close: Apr 28, 2026, 4:00 PM EDT
21.07
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:32 PM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 26 analysts with 12-month price forecasts for Sarepta Therapeutics stock have an average target of 25.85, with a low estimate of 5.00 and a high estimate of 81. The average target predicts an increase of 22.69% from the current stock price of 21.07.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock from 29 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 13 | 13 | 13 | 13 | 13 | 13 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 4 | 4 | 4 | 4 | 4 | 4 |
| Total | 30 | 29 | 29 | 29 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Sell Reiterates $5 | Strong Sell | Reiterates | $5 | -76.27% | Apr 16, 2026 |
| Citigroup | Citigroup | Strong Sell Maintains $9 → $13 | Strong Sell | Maintains | $9 → $13 | -38.30% | Mar 26, 2026 |
| Needham | Needham | Sell Reiterates n/a | Sell | Reiterates | n/a | n/a | Mar 26, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $37 | Buy | Reiterates | $37 | +75.61% | Mar 19, 2026 |
| Mizuho | Mizuho | Buy Maintains $26 → $31 | Buy | Maintains | $26 → $31 | +47.13% | Mar 13, 2026 |
Financial Forecast
Revenue This Year
1.77B
from 2.20B
Decreased by -19.48%
Revenue Next Year
1.47B
from 1.77B
Decreased by -17.01%
EPS This Year
3.13
from -7.13
EPS Next Year
1.68
from 3.13
Decreased by -46.17%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.0B | 2.0B | ||||||
| Avg | 1.8B | 1.5B | ||||||
| Low | 1.4B | 865.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -9.7% | 11.9% | ||||||
| Avg | -19.5% | -17.0% | ||||||
| Low | -36.9% | -51.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 5.86 | 5.18 | ||||||
| Avg | 3.13 | 1.68 | ||||||
| Low | 0.80 | -0.21 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 65.5% | ||||||
| Avg | - | -46.2% | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.